BioCentury
ARTICLE | Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

December 17, 2019 10:59 PM UTC

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the company restructured to focus on HBV vaccine Heplisav-B while scaling back its immuno-oncology program. The company raised $70.1 million in an August follow-on (see "Dynavax Raises $70.1M via Sale of Stock, Warrants").

Merus N.V. (NASDAQ:MRUS) said Tom Logtenberg will step down as president and CEO at year-end after 16 years in the roles. The company has nominated director Bill Lundberg to succeed Logtenberg, pending a shareholder meeting. Merus shares slid in October after the company reported Phase II data for bispecific antibody MCLA-128 (see “Merus Slides After Clinical Update”)...